SK bioscience

SK bioscience (SK), spun-off from SK Chemicals as a subsidiary in 2018, is a member of SK Group which is the third largest enterprise in Korea. After successfully entering into vaccine industry as the number one vaccine distributor in Korea since 2002, SK has successfully established its own R&D capabilities to meet global standards.

SK launched cell culture-based, trivalent and quadrivalent influenza vaccine, SKYCellflu®, in 2015 and 2016 respectively and the two products were prequalified by the World Health Organization in 2019. SKYZoster® Inj. and SKYVaricella® Inj. have also been successfully commercialized in 2017 and 2018, and SKYVaricella® was also prequalified by the WHO in the same year 2019.

A state-of-the-art vaccine manufacturing facility of SK bioscience (L House), located in Andong, Korea, has highly advanced and efficient manufacturing capabilities in producing multiple types of vaccines utilizing its multi-modular and single-use production system. The manufacturing facility started its commercial production of various vaccine products including cell-culture derived influenza vaccines since 2014. In commitment to contribute to the public health and based on its established R&D and manufacturing capabilities, SK bioscience is engaged in different types of partnerships with organizations such as the International Vaccine Institute, Sanofi Pasteur, PATH and others.